Volume 3.21 | Jun 5

Pulmonary Cell News 3.21 June 5, 2014
Pulmonary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
RARRES3 Suppresses Breast Cancer Lung Metastasis by Regulating Adhesion and Differentiation
Researchers showed that RARRES3 downregulation engages metastasis-initiating capabilities by facilitating adhesion of tumor cells to the lung parenchyma. In addition, impaired tumor cell differentiation due to the loss of RARRES3 phospholipase A1/A2 activity also contributes to lung metastasis. [EMBO Mol Med]
Full Article | Press Release
Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by impact factor of the journal)
PEGylation of ORMOSIL Nanoparticles Differently Modulates the In Vitro Toxicity toward Human Lung Cells
Researchers studied the in vitro responses to ORganically MOdified SILica (ORMOSIL) nanoparticles (NPs) in different types of human lung cells to determine the effects of polyethylene glycol (PEG) coating on NP cytotoxicity. [Arch Toxicol] Abstract

MiRNA-21/DDAH1 Pathway Regulates Pulmonary Vascular Responses to Hypoxia
Researchers studied the potential role of miRNA-21 in the regulation of hypoxia-induced changes in asymmetric dimethylarginine (ADMA) metabolism in vitro and in vivo. Hypoxia inhibited dimethylarginine dimethylaminohydrolase (DDAH)1 and DDAH2 expression and increased ADMA levels in cultured human pulmonary endothelial cells. [Biochem J] Abstract

Intracellular Transport of Nanodiamond Particles in Human Endothelial and Epithelial Cells
Scientists examined the penetration human umbilical cord endothelial cells and A549 cells by detonation nanodiamonds modified by adding to, employing four pharmacological inhibitors of endocytosis, using optical, confocal and transmission electron microscopy. [Chem Biol Interact] Abstract

Oxidative Stress Modulates the Expression of Genes Involved in Cell Survival in ΔF508 Cystic Fibrosis Airway Epithelial Cells
Investigators compared the gene expression profile in NuLi-1 cells, with wild-type cystic fibrosis transmembrane conductance regulator and CuFi-1 cells homozygous for ΔF508 mutation cultured at air-liquid interface. [Physiol Genomics] Abstract

Magnolol Inhibits Tumor Necrosis Factor-α-Induced ICAM-1 Expression via Suppressing NF-κB and MAPK Signaling Pathways in Human Lung Epithelial Cells
Scientists examined the effects of magnolol on tumor necrosis factor-α-induced upregulation of intercellular adhesion molecule-1 (ICAM-1), activation of the nuclear factor (NF)-κB and mitogen-activated protein kinase (MAPK) signaling pathway in cultured human pulmonary epithelial cells, and adhesion of human macrophage-like U937 cells to A549 cells. [Inflammation] Abstract

Inhibition of Pseudomonas aeruginosa PAO1 Adhesion to and Invasion of A549 Lung Epithelial Cells by Natural Extracts
Using an A549 lung epithelial cell infection model researchers revealed that a combination of aqueous cranberry extract with ciprofloxacin could completely prevent the adhesion and invasion of P. aeruginosa PAO1 compared to the untreated control. [J Infect Public Health] Abstract


Epigenetic Reprogramming of Human Lung Cancer Cells with the Extract of Bovine Parthenogenetic Oocytes
Researchers investigated whether cancer cells can be epigenetically reprogrammed by oocyte extract. H460 human lung cancer cells were reversibly permeabilized and incubated with the extract of bovine parthenogenetic oocytes. [J Cell Mol Med] Full Article

CXCL16 and CXCR6 Are Coexpressed in Human Lung Cancer In Vivo and Mediate the Invasion of Lung Cancer Cell Lines In Vitro
Scientists explored the significance of CXCL16-CXCR6 axis in the biological functions of lung cancer cell lines in vitro. It was found that CXCL16 had no effects on the proliferating cell nuclear antigen expression of A549, 95D and H292 cells. [PLoS One] Full Article

Tanshinone IIA Induces Cytochrome C-Mediated Caspase Cascade Apoptosis in A549 Human Lung Cancer Cells via the JNK Pathway
The in vitro effects of tanshinone IIA (TSIIA) on apoptosis were investigated in A549 non-small cell lung cancer cells. Researchers showed that TSIIA significantly suppressed the proliferation of A549 cells in a dose-dependent manner. [Int J Oncol] Abstract

Knockdown of Toll-Like Receptor 4 Inhibits Human NSCLC Cancer Cell Growth and Inflammatory Cytokine Secretion In Vitro and In Vivo
Scientists sought to characterize the expression of toll-like receptor 4 (TLR4) in patients with non-small cell lung cancer (NSCLC) and investigated the biological roles of TLR4 in lung metastasis, cell invasion and survival. [Int J Oncol] Abstract

miR-186 Targets ROCK1 to Suppress the Growth and Metastasis of NSCLC Cells
Researchers identified microRNA (miR)-186 as a tumor suppressor in non-small cell lung cancer (NSCLC), which was decreased in NSCLC. Overexpression of miR-186 significantly inhibited proliferation, migration, and invasion of NSCLC cells. [Tumor Biol] Abstract

View On-Demand Webinar: Optimized Differentiation of Bronchial Epithelial Cells
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung Cancer
The authors give an overview of KRAS signaling pathways with an emphasis on novel targets and targeted therapies, using non-small cell lung cancer as a case example. [Clin Cancer Res] Abstract

ALK Inhibitors and Advanced Non-Small Cell Lung Cancer
This review discusses anaplastic lymphoma kinase (ALK) rearrangements, the clinical development and use of crizotinib, and other ALK-tyrosine kinase inhibitors in advanced non-small cell lung cancer. [Int J Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
Clovis Oncology’s CO-1686 Demonstrates Compelling Clinical Activity and Progression-Free Survival (PFS) in Updated Phase I/II Study Results in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Clovis Oncology announced updated findings from the Phase I and early Phase II portions of its ongoing Phase I/II clinical study of CO-1686, the company’s novel, oral, targeted covalent inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of NSCLC in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. [Press release from Clovis Oncology discussing research presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago]
Press Release

Xcovery Presents Interim Phase I Results of X-396 in ALK Positive NSCLC
Xcovery presented preliminary results from a Phase I study of X-396, a potent small molecule anaplastic lymphoma kinase (ALK) inhibitor, that showed X-396 is well tolerated and has antitumor activity in patients with ALK positive non-small cell lung cancer (NSCLC). [Press release from Business Wire discussing research presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

ARIAD Presents Updated Phase I/II Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer
ARIAD Pharmaceuticals, Inc. announced updated clinical results on its investigational tyrosine kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer from an ongoing Phase I/II trial. [Press release from ARIAD Pharmaceuticals, Inc. discussing research presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

Tumor Responses with Crizotinib in MET-Amplified Disease Help Define a New Targetable Form of Lung Cancer
Scientists report the results of a first-in-human, Phase I dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer. [Press release from University of Colorado Cancer Center discussing research presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
Aradigm Receives $5 Million Milestone for Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis
Aradigm Corporation announced that it has received the $5 million milestone payment from Grifols S.A. for the dosing of the first patient in the ORBIT-3 Phase III pivotal clinical trial of Aradigm’s proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis. [Aradigm Corporation] Press Release

Conrad T. Prebys Gives $25 Million to Salk Institute to Support Scientific Research
The Salk Institute for Biological Studies has received a $25 million gift from San Diego philanthropist and former Salk trustee Conrad T. Prebys to support cutting-edge biological research on a wide range of diseases. [The Salk Institute for Biological Studies] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Best of American Society of Clinical Oncology (ASCO) Boston
August 8-9, 2014
Boston, United States

Visit our events page to see a complete list of events in the pulmonary cell community.
NEW Postdoctoral Fellow – Lung Cancer Biomarker Discovery and Applications (Shantou University)

Postdoctoral Position – Molecular and Cell Biology (Cornell University)

PhD Position – Role of Long Non-Coding RNAs in the Lung and During Activation of Lung Fibroblasts (University of Bath)

Junior Research Group Leader Position – Cell-Derived Therapeutics in Chronic Lung Disease (Helmholtz Zentrum München)

Postdoctoral Fellow – Lung Biology and Genomics (Harvard University)

Postdoctoral Research Fellow – Allergic Lung Inflammation (Singapore Immunology Network)

Postdoctoral Fellowship – Malignant Progression of Lung Cancer (MD Anderson Cancer Center)

Research Fellow – Pulmonary Cancer (Mayo Clinic – Rochester)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Pulmonary Cell News: Archives | Events | Contact Us